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tTATE-OF-THE-ART PAPER1123Regadenoson: A New Myocardial Stress Agentael Al Jaroudi, Ami E. Iskandrian
he Food and Drug Administration recently approved regadenoson for stress testing in
onjunction with myocardial perfusion imaging. Regadenoson is a selective A2A agonist.
ctivation of cardiac A2A and A2B adenosine receptors causes vasodilation in the coronary
nd peripheral arterial beds and increases myocardial blood flow. The side effects of
denosine, including negative chronotropism and bronchial constriction, are thought to be
econdary to stimulation of the other adenosine receptors. Clinical trials have shown
egadenoson to be noninferior to adenosine for detection of perfusion abnormalities with
ewer side effects. This review by Al Jaroudi and Iskandrian summarizes the pre-clinical and
linical data on regadenoson regarding its use as a vasodilator stress agent.CLINICAL RESEARCH NTERVENTIONAL CARDIOLOGY1131Incidence and Management of Restenosis After Left Main PCImad Sheiban, Dario Sillano, Giuseppe Biondi-Zoccai, Alaide Chieffo, Antonio Colombo, Sabine Vecchio,
assimo Margheri, Julian P. Gunn, Tushar Raina, Francesco Liistro, Leonardo Bolognese, Michael S. Lee,
onathan Tobis, Claudio Moretti
heiban and colleagues studied the incidence and management of restenosis following drug-
luting stent (DES) implantation for unprotected left main (ULM) disease in over 700
ubjects. Post-DES restenosis in the ULM occurred in 9.7% of patients, 84% of whom were
reated percutaneously. A total of 10% of patients underwent coronary artery bypass grafting,
nd 6% were treated medically. There was only 1 in-hospital major adverse cardiac event
MACE) for repeat percutaneous coronary intervention (PCI) patients. During a median
ollow-up of more than 2 years, patients treated with medical, interventional, and surgical
herapy had the following MACE rates: 50%, 25%, and 14%, respectively. DES restenosis in
he ULM artery can often be managed percutaneously with favorable early and late results.(continued on page A-25)
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EORONARY ARTERY PHYSIOLOGY
1137he Predominant -1-Adrenergic
Receptor Subtype in Human Coronary Arteries is 1Drian C. Jensen, Philip M. Swigart, Marie-Eve Laden, Teresa DeMarco, Charles Hoopes, Paul C. Simpson
ensen and colleagues used explanted human coronary arteries to determine which of the
1-adrenergic receptor (AR) subtypes was most prevalent in human coronary arteries. The
1D subtype was 85% of total coronary 1-AR messenger ribonucleic acid and 75% of total
1-AR protein. In contrast, there was a low prevalence of 1D in the left ventricular
yocardium. Total coronary 1-AR levels were one-third of -ARs, which were 99% of the
2 subtype. This distribution of 1-AR subtypes is similar to the mouse, where myocardial
1A- and 1B-ARs mediate vasodilation and coronary 1Ds mediate vasoconstriction. This
uggests that a 1D-selective antagonist could stimulate coronary vasodilation.ditorial Comment: Oscar Ö. Braun, Paul A. Insel, p. 1146NTIPLATELET THERAPY1149Less Inhibition of Clopidogrel With Pantoprazole Than Omeprazolehomas Cuisset, Corinne Frere, Jacques Quilici, Raphael Poyet, Bénédicte Gaborit, Laurent Bali,
livier Brissy, Pierre-Emmanuel Morange, Marie-Christine Alessi, Jean-Louis Bonnet
meprazole has been reported to significantly decrease the efficacy of clopidogrel. Cuisset and
olleagues randomized post-percutaneous coronary intervention patients to either omeprazole
r pantoprazole to see if both proton pump inhibitors (PPIs) had a similar effect. After 1
onth, patients receiving pantoprazole had a significantly better platelet reactivity index
asoactive stimulated phosphoprotein, but there was no significant difference in adenosine
iphosphate-induced aggregation. These findings suggest that pantoprazole may have less
nterference with clopidogrel and should be used preferentially over omeprazole in patients
ho need treatment with a PPI.YPERTENSION1154Benefit of Amlodipine Over Atenolol Not Affected by Baseline Heart Rateeil R. Poulter, Joanna E. Dobson, Peter S. Sever, Björn Dahlöf, Hans Wedel, Norm R. C. Campbell,
n behalf of the ASCOT Investigators
ome have postulated that patients with high baseline heart rates and hypertension, possibly
aused by high adrenergic tone, may benefit more from a beta-blocker–based antihypertensive
egimen. Poulter and colleagues reanalyzed data from ASCOT (Anglo-Scandinavian Cardiac
utcomes Trial), which randomized patients to either an atenolol- or an amlodipine-based
ntihypertensive regimen to determine if baseline heart rate affected the relative benefits. The
elative risk reduction for total cardiovascular events and procedures with amlodipine was 0.81
nd did not vary with baseline heart rate. Similar results were obtained for coronary and total
troke outcomes. These data suggest that a high baseline heart rate is not an indication for
referential use of beta-blocker–based therapy.
ditorial Comment: Carl J. Lavie, Franz H. Messerli, Richard V. Milani, p. 1162(continued on page A-27)
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uIOMARKERS1165Normal Plasma Levels of cTnI Measured by New High-Sensitivity Assayer Venge, Nina Johnston, Bertil Lindahl, Stefan James
tudies on patients with acute coronary syndromes (ACS) have shown that even minor
levations of cardiac troponins are associated with increased risk of death. However, the
ormal plasma levels of cardiac troponins are not known. Venge and colleagues evaluated the
nalytical and clinical performance of a new hypersensitive cardiac troponin I assay in both
ealthy subjects and in randomly selected patients of the GUSTO IV (Global Utilization of
trategies To open Occluded arteries IV) trial. Cardiac troponin I (cTnI) levels were
easurable in 95% of the healthy subjects. The median level in healthy subjects 60 years
f age was 0.0032 g/l, with the 99th percentile being 0.010 g/l. This high-sensitive cTnI
rototype assay shows that cTnI is detectable in low levels in almost all healthy subjects.ditorial Comment: Judd E. Hollander, p. 1173ERIPHERAL VASCULAR DISEASE1176CKD Predisposes to Both High and Low ABIoachim H. Ix, Ronit Katz, Ian H. De Boer, Brian R. Kestenbaum, Matthew A. Allison, David S. Siscovick,
nne B. Newman, Mark J. Sarnak, Michael G. Shlipak, Michael H. Criqui
low ankle-brachial index (ABI) is sensitive and specific for atherosclerosis; alternatively, a
igh ABI reflects stiffening of the lower limb arteries and has high specificity for medial
rterial calcification. Ix and colleagues studied the relationship between chronic kidney disease
CKD) and ABI in 4,000 elderly subjects. CKD was defined by an estimated glomerular
ltration rate 60 ml/min/1.73 m2. In multivariable models, CKD was associated with both
ow ABI (0.9, relative risk [RR]: 2.0) and high ABI (1.40, RR: 1.6). CKD is associated
ith both the high and low extremes of ABI and may be an important mechanism leading to
ardiovascular disease in persons with CKD.NEWS FROM THE NHLBI EWS FROM THE NHLBI1185Cardiovascular Disease and HIVheryl L. McDonald, Jonathan R. Kaltman
he currently available evidence is that there is an excess risk of cardiovascular events in
uman immunodeficiency virus (HIV)-infected persons. Antiretroviral drugs may be
ssociated with insulin resistance and dyslipidemia, but they are not the only factors likely
nvolved in the increased cardiovascular disease risk. Traditional risk factors may be increased
n these patients, such as increased rates of smoking; HIV itself may affect traditional risk
actors, including lipid profiles; and/or there may be increased underlying inflammation. The
ational Heart, Lung, and Blood Institute encourages the continued partnership of basic and
linical cardiovascular and infectious diseases researchers in their efforts to tackle the still
nanswered questions of cardiovascular disease in HIV/acquired immunodeficiency syndrome.
